Back to Blog

Hydrosalpinx: Symptoms, Diagnosis and What to Do Before IVF

Dr. Senai Aksoy · · Updated · 8 min read
Medically reviewed on 8 October 2026 - Dr. Senai Aksoy
Woman with dark wavy hair sitting on a wooden bench by a window in a terracotta-walled room, looking outside

Key Takeaways

Hydrosalpinx is a fallopian tube that has become blocked and filled with fluid. It often causes no symptoms and is found during a fertility work-up. When IVF is planned and a hydrosalpinx is clearly present, especially if it is visible on ultrasound, guidelines support treating the tube before transfer, usually by salpingectomy or proximal tubal occlusion rather than aspiration. Randomized trials show more clinical pregnancies after surgery and some report better delivery rates, but the overall evidence on live birth remains limited and uncertain.

Key evidence: ASRM — Tubal surgery in the ART era (2021) Cochrane 2020 — Surgical treatment for tubal disease before IVF WHO — Infertility guideline recommendations (Hum Reprod 2026)

Salpingitis: Symptoms, Causes and Impact on Fertility — Dr. Senai Aksoy

Salpingitis: Symptoms, Causes and Impact on Fertility — Dr. Senai Aksoy

This video is in French; English and Arabic dubbing and subtitles are available in the YouTube player settings. It complements the article but does not replace an individual medical assessment.

On this page

Hydrosalpinx before the next transfer

Hydrosalpinx means that a fallopian tube has become blocked and filled with fluid. It often follows pelvic infection or inflammation, endometriosis, or previous surgery. The tube becomes distended and no longer functions normally.

Some people notice pelvic pain, pressure, or unusual discharge. Many discover it only during an infertility evaluation, for example on a hysterosalpingogram (HSG) or an ultrasound. That finding can change the timing of the next IVF cycle.

This guide focuses on the practical transfer-timing question: why a specialist may pause the cycle, which options can be discussed, and how this decision relates to our broader overview of hydrosalpinx treatment and infertility.

Dr. Aksoy’s Approach

“When an ultrasound or HSG suggests a hydrosalpinx, I first look at how certain the diagnosis is, how distended the tube is, and whether the fluid can reach the uterine cavity. A hydrosalpinx that is clearly visible on ultrasound can matter even when fluid passing into the uterus has not been shown directly.

“If salpingectomy can be performed safely without compromising the ovarian blood supply, it is often the preferred surgical option. When dense adhesions make removal hazardous, proximal tubal occlusion may be a reasonable alternative. The choice is anatomical and individual; it is not automatic for every patient.

“The aim is not to make a promise about one future cycle. It is to address a finding that may interfere with the uterine environment before an embryo is transferred.”

Why it matters for fertility

Hydrosalpinx can affect fertility through more than one mechanism:

For pregnancy outcomes the evidence points in the same direction; for live birth it is less certain, and the studies answer different questions. The Strandell randomized trial compared salpingectomy with no intervention before IVF in 204 women. Clinical pregnancy was not significantly different (36.6% vs 23.9%, P = 0.067), but more women went on to deliver after salpingectomy (28.6% vs 16.3%, P = 0.045). The clearest differences were in women with bilateral hydrosalpinx or hydrosalpinx visible on ultrasound. In cumulative follow-up of the same trial (186 women, 452 cycles), salpingectomy was associated with a higher birth rate (hazard ratio 2.1, 95% CI 1.6–3.6), and the difference was larger when the hydrosalpinx was visible on ultrasound (hazard ratio 3.8, 95% CI 1.5–9.2). Because 24 of the 77 women first assigned to no surgery later had salpingectomy, this follow-up shows an association rather than a purely randomized comparison.

In a separate systematic review and meta-analysis of 14 observational studies, hydrosalpinx was associated with a higher risk of pregnancy loss (RR 1.74, 95% CI 1.43–2.12). This is an association, not proof that hydrosalpinx caused every individual loss. In the same review, pooled data from seven randomized and six observational studies of treatment showed about half the risk of pregnancy loss after treatment (RR 0.46, 95% CI 0.34–0.63). Nearly all participants conceived through IVF, so the evidence is less certain for natural conception.

Common causes

The most common underlying cause is previous pelvic inflammatory disease, often linked to Chlamydia trachomatis or Neisseria gonorrhoeae. Other causes include:

The cause matters for the wider fertility assessment. For transfer planning, the more immediate questions are how clearly the hydrosalpinx is seen and whether its fluid can reach the uterine cavity.

Symptoms and clinical presentation

Hydrosalpinx may cause physical symptoms, but it can also be silent:

Symptoms alone cannot confirm or exclude hydrosalpinx. The diagnosis and next step depend on appropriate imaging and the wider clinical picture.

How it is diagnosed

Evaluation usually combines targeted imaging with the clinical history:

Bringing the original HSG DICOM files or clear imaging reports to a consultation can help avoid unnecessary repeat testing.

Why it can lower IVF success

The ASRM committee opinion on tubal surgery describes several possible mechanisms: mechanical flushing from the uterine cavity, reduced endometrial receptivity, and direct effects of the fluid on the embryo. The exact mechanism is still not fully understood. The ASRM opinion also notes that hydrosalpinges visible on ultrasound may have a larger effect, and that even a hydrosalpinx on one side has been linked to lower IVF pregnancy rates, which improved after that tube was removed. The decision therefore does not rest only on showing that fluid reaches the uterus.

Assessing the hydrosalpinx before transfer can help the team plan the sequence of treatment, retrieval, and embryo transfer. It may also avoid waiting until after repeated failed attempts to revisit the same finding. For more detail on the options, see our companion article on hydrosalpinx treatment and infertility.

Treatment options before transfer

When IVF is planned and a hydrosalpinx is clearly present, especially if it is visible on ultrasound, current guidance supports treating the tube before transfer. The ASRM committee opinion gives laparoscopic salpingectomy the leading role and also counts proximal tubal occlusion as an effective alternative; it adds that aspiration, with or without sclerotherapy, may be better than no treatment but needs more study. The WHO guideline suggests either salpingectomy or tubal occlusion rather than transvaginal aspiration of the fluid, and offers aspiration only where surgery is not available or feasible; both WHO statements are conditional recommendations based on very low-certainty evidence.

What do the trials show? In the Cochrane review of 11 randomized trials (1,386 women), salpingectomy probably increases clinical pregnancy compared with no surgery (RR 2.02, 95% CI 1.44–2.82; moderate certainty), and proximal tubal occlusion may do so as well (RR 3.21, 95% CI 1.72–5.99; low certainty). The Cochrane review had no pooled live-birth data for these comparisons, and none of its trials followed long-term fertility. A 2025 network meta-analysis of randomized trials did not show that any treatment significantly increased live birth compared with no treatment, and found no difference in live birth between methods.

Ovarian reserve after surgery. Studies do not agree. One meta-analysis found that AMH and antral follicle count fell more after salpingectomy than after proximal occlusion in the short term, with long-term effects uncertain. Another meta-analysis found no significant fall before versus after surgery, but lower values in case-control comparisons with women who had no surgery; the authors concluded that, although not conclusive, ovarian reserve does appear lower after salpingectomy. In the Scandinavian trial, 26 women who had salpingectomy between IVF cycles showed no difference in ovarian response before and after surgery. This is why the surgical technique matters, as Dr. Aksoy explains in the questions below.

If immune-based testing or treatment is being discussed after failed IVF, first make sure the tubal finding has been assessed properly. That is a separate question from whether an immune add-on helps; imaging, medical history, and the strength of the evidence should guide the sequence. See our overview on immune treatments after failed IVF.

Egg retrieval first or surgery first?

Treating a hydrosalpinx before embryo transfer does not always mean operating before egg retrieval. The order is an individual planning decision rather than a fixed rule.

Dr. Aksoy’s approach to timing

“For me, the most important distinction is that egg retrieval and embryo transfer do not have to happen at the same time. If the patient is young, her ovarian reserve is good and I do not expect the surgery to be difficult, I prefer to treat the hydrosalpinx first. But in women approaching 40, especially when ovarian reserve is low, or when hydrosalpinx on both sides or severe adhesions will make the surgery difficult, I am more inclined to discuss collecting the eggs first and freezing the embryos, because we have to weigh the chance that surgery affects ovarian blood supply and reserve, as well as the time lost to age.

“On the other hand, if a large hydrosalpinx blocks our access to the ovary, if there is an active infection, or if the risk of injuring the tube during egg collection is high, I may choose surgery first. If frozen embryos are already available, my priority is to treat the hydrosalpinx and then transfer. If salpingectomy is risky for the ovary, proximal tubal occlusion can also be considered.

“The principle that does not change for me is that I do not move to embryo transfer before a clinically significant hydrosalpinx is treated. Whether surgery comes before or after egg retrieval depends on the patient’s age, reserve and pelvic anatomy.”

Practical checklist before another transfer

  1. Ask your fertility specialist to review the HSG or ultrasound images, not only the written report.
  2. Clarify whether the hydrosalpinx is on one side or both, how clearly it is seen, and whether its fluid may reach the uterine cavity.
  3. Ask why salpingectomy or proximal occlusion is being considered before embryo transfer.
  4. Discuss the timing of ovarian stimulation, egg retrieval, and surgery if pelvic access may be difficult.
  5. Keep the surgical and IVF timelines together so that the next step is clear, especially when care involves travel.

Frequently Asked Questions for Dr. Aksoy

Does hydrosalpinx always need surgery, and can antibiotics or time clear it?

No, not every hydrosalpinx needs surgery. In some patients, for example those without symptoms, who are not planning a pregnancy, or whose other tube is healthy, follow-up may be possible depending on the situation. But because hydrosalpinx is usually linked to lasting damage and blockage of the tube, I do not expect it to clear completely on its own. Antibiotics can treat an active infection, but they do not remove the adhesions and damage in the tube.

When IVF is planned and the hydrosalpinx is clearly present, I recommend removing the tube, or closing its connection to the uterus, before embryo transfer, because hydrosalpinx fluid may harm IVF success. What decides surgery for me is not only fluid in the tube. It is the patient’s symptoms, the condition of the tube and her pregnancy plan. A healthy opposite tube preserves the chance of natural pregnancy, but on its own it does not remove the negative effect of a hydrosalpinx on IVF.

Does treating hydrosalpinx mean removing the ovary, and how do you protect it?

No. When salpingectomy is done for hydrosalpinx, the aim is to remove the diseased tube, not the ovary. Normally the ovary stays in place and keeps working. Because the tube and the ovary share blood vessel connections, the surgical technique matters. I work as close to the tube as possible, protect the ovarian vessels and avoid unnecessary electrical energy, to reduce the risk of harming ovarian reserve.

Study results are not all the same, but we know that ovarian blood supply and reserve can be affected, especially in difficult operations. For that reason, in patients with a low AMH or who plan IVF later, an ovary-sparing surgical approach matters a great deal to me.

Is hydrosalpinx dangerous, can it burst, and when should pain or discharge send you to the emergency room?

Hydrosalpinx is most often not a life-threatening condition, and in some women it is found without any symptoms. But a damaged tube can reduce the chance of natural pregnancy and may increase the risk of ectopic pregnancy. Patients sometimes ask, “Can the tube burst?” Spontaneous rupture of a simple hydrosalpinx is extremely rare. What we watch for more closely is an active infection of the tube with pus collecting in it, called pyosalpinx, or a tubo-ovarian abscess. These conditions can cause serious infection and, rarely, rupture of the abscess.

Mild, chronic pelvic pain is not always an emergency. But if there is sudden severe abdominal pain, fever, foul-smelling discharge, nausea and vomiting, fainting or marked weakness, a woman needs to be assessed without waiting. If pregnancy is possible, an ectopic pregnancy must always be excluded as well. If fever or increasing abdominal pain develops in the days after egg collection, she should also be assessed without waiting.

Sources

For educational purposes only. Last editorial review: 8 October 2026.

Next step

A question about your own case?

An article can set out the general picture, but not what applies to your own history. If you would like your situation looked at, you can send your questions and any previous reports to the medical team.

For privacy, please send only information needed for an initial reply. Ask the team which secure channel to use for medical reports or identity documents.

Request a medical review

Add as a Preferred Source on Google

You can add draksoyivf.com as one of your preferred health information sources on Google.

Add on Google
Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

Instagram YouTube

The content has been created by Dr. Senai Aksoy and medically approved.

Privacy and measurement choices

Necessary storage keeps the site working. If you accept, Google Analytics and Microsoft Clarity may use optional cookies to help us understand site use and measure advertising. Personalized advertising remains off. If you decline, optional cookies stay off; Google Consent Mode may still send limited, cookieless measurement signals. You can change your choice later.

Privacy policy